Clinical trials: Eczema
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing…
- Trial name
- NCT04643457
- Testing
- UCB9741
- Where
- 10 sites in Bulgaria, Germany and 2 more
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy, Atopic Dermatitis
A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis
The clinical study consists of three parts: Part 1 with healthy volunteers. Part 2 and Part 3 including subjects with moderate to severe atopic dermatitis (a skin disease).
- Trial name
- NCT03689829
- Testing
- MOR106
- Where
- 15 sites in Germany, Spain and 2 more
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
- Trial name
- NCT03587805
- Testing
- Tralokinumab
- Where
- 309 sites in United States, Belgium and 9 more
- Volunteers
- 1,672 people
- Sponsor
- LEO Pharma
Mild to Moderate Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients
This study aims to evaluate the efficacy and safety of IN-115314 Ointment in mild to moderate atopic dermatitis adult patients
- Trial name
- NCT07073677
- Testing
- IN-115314 Ointment 1%, IN-115314 Ointment 3%
- Where
- South Korea
- Volunteers
- 162 people
- Sponsor
- HK inno.N Corporation
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis, Eczema
A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
- Trial name
- NCT03089229
- Testing
- HAT01H Cream, Vehicle Cream
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Haus Bioceuticals
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
A multicenter, randomized, double-blind, vehicle controlled phase II clinical study
- Trial name
- NCT06891040
- Testing
- VC005 groups
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis
To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT02456480
- Testing
- CLS001, Vehicle
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- Maruho Co., Ltd.
Atopic Dermatitis
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
The main purpose of this trial is to investigate what happens to the trial drug in the body and to confirm that it is safe to use and effective for treating atopic dermatitis (AD) in children.
- Trial name
- NCT05388760
- Testing
- Tralokinumab
- Where
- 11 sites in Czechia, France and 3 more
- Volunteers
- 28 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled…
- Trial name
- NCT07054736
- Testing
- XKH001 Injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Atopic Dermatitis
Jaktinib Hydrochloride Cream For Atopic Dermatitis
This study includes a dose escalation part and a dose extension part.
- Trial name
- NCT04435392
- Testing
- Jaktinib Hydrochloride Cream
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Dermatitis, Atopic
Protopic Ointment in Children Atopic Eczema
Children with atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks. They could continue during 3 more weeks once a day if needed.
- Trial name
- NCT00689832
- Testing
- Tacrolimus 0.03%, Fluticasone 0.005%
- Where
- France
- Volunteers
- 487 people
- Sponsor
- Astellas Pharma Inc
Dermatitis, Atopic, Dermatitis
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- ADhere-J (NCT04760314)
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 37 sites in Japan
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis
The purpose of this study is to determine the safety and efficacy of three concentrations of ZK 245186 ointment and vehicle on increasing body surface areas for the treatment of atopic dermatitis and to obtain dose-response…
- Trial name
- NCT00944632
- Testing
- ZK 245186
- Where
- 3 sites in South Africa
- Volunteers
- 64 people
- Sponsor
- Bayer
Atopic Dermatitis, Pruritus
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis.
- Trial name
- NCT04490109
- Testing
- B244, Vehicle
- Where
- 56 sites in United States
- Volunteers
- 547 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
Evalution the Safety and Efficacy in Atopic Dermatitis Patients
A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year results from the K0102 extension study
- Trial name
- NCT03962387
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.